Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

PloS one - 1 Jan 2011

Janku Filip, Lee J Jack, Tsimberidou Apostolia M, Hong David S, Naing Aung, Falchook Gerald S, Fu Siqing, Luthra Rajyalakshmi, Garrido-Laguna Ignacio, Kurzrock Razelle

Abstract excerpt

BACKGROUND: Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis. METHODS: Tumor tissues from 504 patients with diverse cancers referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center starting in October 2008 were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 21829508
DOI: 10.1371/journal.pone.0022769
PMCID: PMC3146490

Genes

KRAS
BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.PMID 21829508Read ↗

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.Semantic proximity Read ↗

PIK3CA mutations in advanced cancers: characteristics and outcomes.Semantic proximity Read ↗

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.Semantic proximity Read ↗

KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania.Semantic proximity Read ↗

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.Semantic proximity Read ↗

Oncogenic PI3K and its role in cancer.Semantic proximity Read ↗

High incidence of PI3K pathway gene mutations in South Indian cervical cancers.Semantic proximity Read ↗

The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.Semantic proximity Read ↗

PIK3CA gene aberrancy and role in targeted therapy of solid malignancies.Semantic proximity Read ↗

Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.Semantic proximity Read ↗

Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers.Semantic proximity Read ↗

The Landscape of PIK3CA Mutations in Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.